{"title":"将反义寡核苷酸和免疫调节剂的序贯疗法作为治愈 HBV 的一种策略","authors":"Henry Lik Yuen Chan","doi":"10.1016/j.jhep.2024.10.011","DOIUrl":null,"url":null,"abstract":"<h2>Section snippets</h2><section><section><h2>Financial support</h2>none</section></section><section><section><h2>Declaration of Competing Interest:</h2>HLY Chan is an advisor for Aligos, Glaxo-Smith-Kline, Roche, Vaccitech, Virion Therapeutics; a speaker for Echossens, Gilead, Roche; and a data management board member for Aligos, Arbutus, Precision BioSciences, Roche, Vaccitech, Zhimeng Therapeutics.</section></section>","PeriodicalId":15888,"journal":{"name":"Journal of Hepatology","volume":"30 1","pages":""},"PeriodicalIF":26.8000,"publicationDate":"2024-10-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Sequential therapy with antisense oligonucleotide and immune modulator as a strategy for HBV cure\",\"authors\":\"Henry Lik Yuen Chan\",\"doi\":\"10.1016/j.jhep.2024.10.011\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<h2>Section snippets</h2><section><section><h2>Financial support</h2>none</section></section><section><section><h2>Declaration of Competing Interest:</h2>HLY Chan is an advisor for Aligos, Glaxo-Smith-Kline, Roche, Vaccitech, Virion Therapeutics; a speaker for Echossens, Gilead, Roche; and a data management board member for Aligos, Arbutus, Precision BioSciences, Roche, Vaccitech, Zhimeng Therapeutics.</section></section>\",\"PeriodicalId\":15888,\"journal\":{\"name\":\"Journal of Hepatology\",\"volume\":\"30 1\",\"pages\":\"\"},\"PeriodicalIF\":26.8000,\"publicationDate\":\"2024-10-17\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Journal of Hepatology\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1016/j.jhep.2024.10.011\",\"RegionNum\":1,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"GASTROENTEROLOGY & HEPATOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Hepatology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1016/j.jhep.2024.10.011","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"GASTROENTEROLOGY & HEPATOLOGY","Score":null,"Total":0}
Sequential therapy with antisense oligonucleotide and immune modulator as a strategy for HBV cure
Section snippets
Financial support
none
Declaration of Competing Interest:
HLY Chan is an advisor for Aligos, Glaxo-Smith-Kline, Roche, Vaccitech, Virion Therapeutics; a speaker for Echossens, Gilead, Roche; and a data management board member for Aligos, Arbutus, Precision BioSciences, Roche, Vaccitech, Zhimeng Therapeutics.
期刊介绍：
The Journal of Hepatology is the official publication of the European Association for the Study of the Liver (EASL). It is dedicated to presenting clinical and basic research in the field of hepatology through original papers, reviews, case reports, and letters to the Editor. The Journal is published in English and may consider supplements that pass an editorial review.
京公网安备 11010802042870号
京ICP备2023020795号-1
分享
求助内容：
应助结果提醒方式：
扫码关注我们
